Bridgewater Associates LP Has $1.04 Million Stake in Teladoc Health, Inc. (NYSE:TDOC)

Bridgewater Associates LP decreased its holdings in Teladoc Health, Inc. (NYSE:TDOC) by 52.3% during the third quarter, Holdings Channel.com reports. The firm owned 112,806 shares of the health services provider’s stock after selling 123,580 shares during the period. Bridgewater Associates LP’s holdings in Teladoc Health were worth $1,036,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in TDOC. Price T Rowe Associates Inc. MD increased its holdings in shares of Teladoc Health by 6.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 86,377 shares of the health services provider’s stock valued at $1,305,000 after purchasing an additional 5,188 shares during the period. QRG Capital Management Inc. increased its holdings in shares of Teladoc Health by 15.6% in the 2nd quarter. QRG Capital Management Inc. now owns 25,395 shares of the health services provider’s stock valued at $248,000 after purchasing an additional 3,420 shares during the period. SG Americas Securities LLC increased its holdings in shares of Teladoc Health by 43.8% in the 2nd quarter. SG Americas Securities LLC now owns 54,467 shares of the health services provider’s stock valued at $533,000 after purchasing an additional 16,580 shares during the period. Granite Bay Wealth Management LLC acquired a new position in shares of Teladoc Health in the 2nd quarter valued at about $1,111,000. Finally, Diversified Trust Co bought a new stake in shares of Teladoc Health in the 2nd quarter valued at approximately $151,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Stock Up 4.8 %

Shares of TDOC stock opened at $11.98 on Monday. Teladoc Health, Inc. has a 12 month low of $6.76 and a 12 month high of $22.54. The firm has a market cap of $2.06 billion, a PE ratio of -2.08 and a beta of 0.90. The stock has a 50 day moving average of $9.38 and a 200-day moving average of $9.25. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The company had revenue of $640.51 million during the quarter, compared to analyst estimates of $630.50 million. On average, equities analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Insider Activity at Teladoc Health

In other Teladoc Health news, COO Michael Willem Waters sold 4,218 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $30,200.88. Following the completion of the transaction, the chief operating officer now directly owns 78,309 shares in the company, valued at $560,692.44. This represents a 5.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Thomas Mckinley acquired 4,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were bought at an average price of $7.69 per share, with a total value of $30,760.00. Following the completion of the purchase, the director now directly owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. This represents a 11.40 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 20,051 shares of company stock worth $143,565. 0.95% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TDOC. Royal Bank of Canada boosted their price target on Teladoc Health from $9.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Piper Sandler lowered their price target on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. JPMorgan Chase & Co. lowered their price target on Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, August 26th. Barclays boosted their price target on Teladoc Health from $10.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group began coverage on Teladoc Health in a research note on Friday, November 15th. They issued a “buy” rating and a $14.00 price target for the company. Fourteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and a consensus target price of $12.08.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.